Male breast cancer: a closer look at patient and tumor characteristics and factors that affect survival using the National Cancer Database

[1]  L. Eriksson,et al.  Time from breast cancer diagnosis to therapeutic surgery and breast cancer prognosis: A population‐based cohort study , 2018, International journal of cancer.

[2]  Matthew J. Selleck,et al.  Impact of Breast Reconstruction on Time to Definitive Surgical Treatment, Adjuvant Therapy, and Breast Cancer Outcomes , 2018, Annals of Surgical Oncology.

[3]  A. Terando,et al.  Timing of Breast Cancer Surgery—How Much Does It Matter? , 2017, The breast journal.

[4]  A. Santoro,et al.  Controversies in clinicopathological characteristics and treatment strategies of male breast cancer: A review of the literature. , 2017, Critical reviews in oncology/hematology.

[5]  D. Dabbs,et al.  Male Breast Cancer: A Single-Institution Clinicopathologic and Immunohistochemical Study. , 2017, American journal of clinical pathology.

[6]  R. Nelson,et al.  Time to Treatment: Measuring Quality Breast Cancer Care , 2016, Annals of Surgical Oncology.

[7]  P. Abreu,et al.  Male breast cancer: Looking for better prognostic subgroups. , 2016, Breast.

[8]  J. Beck,et al.  Time to Surgery and Breast Cancer Survival in the United States. , 2016, JAMA oncology.

[9]  A. Luini,et al.  Outcome of male breast cancer: a matched single-institution series. , 2014, Clinical breast cancer.

[10]  L. Ottini.  Male breast cancer: a rare disease that might uncover underlying pathways of breast cancer , 2014, Nature Reviews Cancer.

[11]  R. Rabinovitch,et al.  Management of male breast cancer in the United States: a surveillance, epidemiology and end results analysis. , 2013, International journal of radiation oncology, biology, physics.

[12]  S. Tommasi,et al.  Male breast cancer: genetics, epigenetics, and ethical aspects. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Hongjian Yang,et al.  The prognostic significance of molecular subtype for male breast cancer: a 10-year retrospective study. , 2013, Breast.

[14]  D. Patten,et al.  New approaches in the management of male breast cancer. , 2013, Clinical breast cancer.

[15]  M. Zuraek,et al.  Gender Differences in Breast Cancer: Analysis of 13,000 Breast Cancers in Men from the National Cancer Data Base , 2012, Annals of Surgical Oncology.

[16]  K. Czene,et al.  Incidence and outcome of male breast cancer: an international population-based study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Bergh,et al.  Multidisciplinary meeting on male breast cancer: summary and research recommendations. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  V. Speirs,et al.  The rising incidence of male breast cancer , 2009, Breast Cancer Research and Treatment.

[19]  A. Stang,et al.  Decline in breast cancer incidence in the United States: what about male breast cancer? , 2008, Breast Cancer Research and Treatment.

[20]  K. Gelmon,et al.  The 2000 EBCTCG overview: a widening gap , 2005, The Lancet.

[21]  A. Troxel,et al.  Men with breast cancer have better disease-specific survival than women. , 2004, Archives of surgery.

[22]  G. Hortobagyi,et al.  Breast carcinoma in men , 2004, Cancer.

[23]  K. Zedeler,et al.  Postoperative Radiotherapy in High-Risk Premenopausal Women with Breast Cancer Who Receive Adjuvant Chemotherapy , 1997 .

[24]  N. Le,et al.  Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. , 1997, The New England journal of medicine.

[25]  Early Breast Cancer Trialists' Collaborative Group.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992, The Lancet.

[26]  A. D. Schryver,et al.  Systemic treatment of early breast-cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women: 1 , 1992 .

[27]  Earlybreastcancertrialistscol,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992, The Lancet.

[28]  D. Kinne.  Management of male breast cancer. , 1991, Oncology.

[29]  I. Fentiman,et al.  Cancer in the elderly: why so badly treated? , 1990, The Lancet.